Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)

[1]  C. Fonatsch,et al.  Cytogenetic findings in 179 patients with myelodysplastic syndromes , 1995, Annals of Hematology.

[2]  U. Germing,et al.  Risk Assessment in Chronic Myelomonocytic Leukemia (CMML) , 2004, Leukemia & lymphoma.

[3]  C. Schoch,et al.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.

[4]  H. Chi,et al.  Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome , 2003, Leukemia.

[5]  J. Bueno,et al.  Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. , 2002, Leukemia research.

[6]  Terry L. Smith,et al.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. , 2002, Blood.

[7]  O. Haas,et al.  Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems , 2001, Annals of Hematology.

[8]  C. Fonatsch,et al.  Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. , 2001, Leukemia research.

[9]  U. Germing,et al.  Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.

[10]  J. Bennett,et al.  World Health Organization classification of the acute leukemias and myelodysplastic syndrome. , 2000, International journal of hematology.

[11]  Cervera,et al.  Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes , 2000, British journal of haematology.

[12]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Pfeilstöcker,et al.  Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics , 1999, British journal of haematology.

[15]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[16]  H. Mizoguchi,et al.  Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. , 1995, Leukemia research.

[17]  U. Germing,et al.  Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. , 1994, Leukemia.

[18]  A. Tobler,et al.  Prediction of 18 months survival in patients with primary myelodysplastic syndrome: a regression model and scoring system based on the combination of chromosome findings and the bournemouth score , 1994 .

[19]  A. Duhamel,et al.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.

[20]  S. Asano,et al.  Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. , 1993, Leukemia.

[21]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.

[22]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[23]  H. Kantarjian,et al.  Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferon. , 1987, Leukemia.

[24]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.

[25]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.